BioCentury
ARTICLE | Company News

Covis, Sanofi sales and marketing update

April 15, 2013 7:00 AM UTC

Sanofi granted Covis U.S. rights to Nilandron nilutamide; Plaquenil hydroxychloroquine; Rilutek riluzole; Uroxatral alfuzosin; and Kayexalate sodium polystyrene. Covis said aggregate U.S. sales in 2012 for the products were $114.6 million. Covis will market the products through its Covis Pharmaceuticals Inc. subsidiary. Sanofi will manufacture and supply the products. The companies declined to disclose terms of the agreement and could not be reached for details. ...